ACUTE MYELOID LEUKEMIA

Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition

Abstract

Pan-RAF inhibitors have shown promise as antitumor agents in RAS and RAF mutated solid cancers. However, the efficacy of pan-RAF inhibitors in acute myeloid leukemia (AML) has not previously been explored. In AML, the RAS–RAF–MEK–ERK (MAPK) pathway is one of the most aberrantly activated oncogenic pathways, but previous targeting of this pathway by MEK inhibitors has not proven effective in clinical trials. Here we show that pan-RAF inhibition, but not MEK inhibition, induced cell death in 29% of AML samples while being nontoxic toward healthy bone marrow cells. Mechanistically, pan-RAF inhibition downregulated MCL1 protein synthesis and induced apoptosis in cells dependent on MCL1 for their survival. Furthermore, the combination of a pan-RAF and a BCL2 inhibitor overcame resistance to either compound alone in AML cell lines, as well as synergized and induced long-term responses ex vivo in AML patient samples relapsed or refractory to azacitidine + venetoclax treatment. Together, our results indicate that pan-RAF inhibition, alone or in combination with BCL2 inhibition, is a promising treatment strategy for AML.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Pan-RAF inhibition is cytotoxic to AML blasts ex vivo.
Fig. 2: Pan-RAF inhibition is more effective than MEK inhibition to induce apoptosis in AML cell lines.
Fig. 3: pan-RAF inhibition downregulates MCL1 protein expression.
Fig. 4: Pan-RAF inhibition downregulates MCL1 and induces death in cells dependent on MCL1 for their survival.
Fig. 5: Acquired resistance to MCL1 inhibition concomitantly confers resistance to pan-RAF inhibition.
Fig. 6: Pan-RAF inhibition downregulates MCL1 protein synthesis.
Fig. 7: Combined inhibition of pan-RAF and BCL2 overcomes resistance to either compound alone.
Fig. 8: Primary AML patient samples relapsed or refractory to azacitidine + venetoclax treatment are sensitive to combined inhibition of pan-RAF and BCL2.

References

  1. 1.

    Dohner K, Paschka P, Dohner H. [Acute myeloid leukemia]. Internist. 2015;56:354–63.

    CAS  Article  Google Scholar 

  2. 2.

    Bohl SR, Bullinger L, Rucker FG. New targeted agents in acute myeloid leukemia: new hope on the rise. Int J Mol Sci. 2019;20:1983.

    CAS  Article  Google Scholar 

  3. 3.

    Ricciardi MR, McQueen T, Chism D, Milella M, Estey E, Kaldjian E, et al. Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia. 2005;19:1543–9.

    CAS  Article  Google Scholar 

  4. 4.

    Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 2000;19:624–31.

    CAS  Article  Google Scholar 

  5. 5.

    Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Basecke J, et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia. 2011;25:1080–94.

    CAS  Article  Google Scholar 

  6. 6.

    Reuter CW, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood. 2000;96:1655–69.

    CAS  Article  Google Scholar 

  7. 7.

    Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, et al. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014;20:490–8.

    CAS  Article  Google Scholar 

  8. 8.

    Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, et al. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer. 2016;122:1871–9.

    CAS  Article  Google Scholar 

  9. 9.

    Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, et al. Phase II trial of MEK inhibitor Binimetinib (MEK162) in RAS-mutant acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2019;19:142–48.e1.

    Article  Google Scholar 

  10. 10.

    Peng SB, Henry JR, Kaufman MD, Lu WP, Smith BD, Vogeti S, et al. Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers. Cancer Cell. 2015;28:384–98.

    CAS  Article  Google Scholar 

  11. 11.

    Yao Z, Gao Y, Su W, Yaeger R, Tao J, Na N, et al. RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nat Med. 2019;25:284–91.

    CAS  Article  Google Scholar 

  12. 12.

    Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan XJ, et al. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. Oncotarget. 2017;8:9251–66.

    Article  Google Scholar 

  13. 13.

    Wei WJ, Sun ZK, Shen CT, Song HJ, Zhang XY, Qiu ZL, et al. Obatoclax and LY3009120 efficiently overcome vemurafenib resistance in differentiated thyroid cancer. Theranostics. 2017;7:987–1001.

    CAS  Article  Google Scholar 

  14. 14.

    Zhao X, Wang X, Fang L, Lan C, Zheng X, Wang Y, et al. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer. Cancer Lett. 2017;402:61–70.

    CAS  Article  Google Scholar 

  15. 15.

    Muller E, Bauer S, Stuhmer T, Mottok A, Scholz CJ, Steinbrunn T, et al. Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS. Leukemia. 2017;31:922–33.

    CAS  Article  Google Scholar 

  16. 16.

    Testa U, Riccioni R. Deregulation of apoptosis in acute myeloid leukemia. Haematologica. 2007;92:81–94.

    CAS  Article  Google Scholar 

  17. 17.

    Soderquist RS, Crawford L, Liu E, Lu M, Agarwal A, Anderson GR, et al. Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity. Nat Commun. 2018;9:3513.

    Article  Google Scholar 

  18. 18.

    Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, et al. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 2018;8:1566–81.

    CAS  Article  Google Scholar 

  19. 19.

    Moujalled DM, Pomilio G, Ghiurau C, Ivey A, Salmon J, Rijal S, et al. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. Leukemia. 2019;33:905–17.

    CAS  Article  Google Scholar 

  20. 20.

    Phillips DC, Jin S, Gregory GP, Zhang Q, Xue J, Zhao X, et al. A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies. Leukemia. 2019;34:1646–57.

    Article  Google Scholar 

  21. 21.

    Rahmani M, Davis EM, Bauer C, Dent P, Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem. 2005;280:35217–27.

    CAS  Article  Google Scholar 

  22. 22.

    Pan R, Ruvolo V, Mu H, Leverson JD, Nichols G, Reed JC, et al. Synthetic lethality of combined Bcl-2 inhibition and p53 activation in AML: mechanisms and superior antileukemic efficacy. Cancer Cell. 2017;32:748–60.e6.

    CAS  Article  Google Scholar 

  23. 23.

    Powell JA, Lewis AC, Zhu W, Toubia J, Pitman MR, Wallington-Beddoe CT, et al. Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia. Blood. 2017;129:771–82.

    CAS  Article  Google Scholar 

  24. 24.

    Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature. 2010;463:103–7.

    CAS  Article  Google Scholar 

  25. 25.

    Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B, et al. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia. 2012;26:778–87.

    CAS  Article  Google Scholar 

  26. 26.

    Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, et al. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica. 2019;105:697–707.

    Article  Google Scholar 

  27. 27.

    Zhang W, Ruvolo VR, Gao C, Zhou L, Bornmann W, Tsao T, et al. Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells. Mol Cancer Ther. 2014;13:1848–59.

    CAS  Article  Google Scholar 

  28. 28.

    Nishioka C, Ikezoe T, Yang J, Yokoyama A. Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and down-regulation of Mcl-1. Apoptosis. 2010;15:795–804.

    CAS  Article  Google Scholar 

  29. 29.

    Karjalainen R, Pemovska T, Popa M, Liu M, Javarappa KK, Majumder MM, et al. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. Blood. 2017;130:789–802.

    CAS  Article  Google Scholar 

  30. 30.

    Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 2013;3:1416–29.

    CAS  Article  Google Scholar 

  31. 31.

    Yadav B, Pemovska T, Szwajda A, Kulesskiy E, Kontro M, Karjalainen R, et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci Rep. 2014;4:5193.

    CAS  Article  Google Scholar 

  32. 32.

    Potdar S, Ianevski A, Mpindi J-P, Bychkov D, Fiere C, Ianevski P, et al. Breeze: an integrated quality control and data analysis application for high-throughput drug screening. Bioinformatics. 2020;36:3602–4.

    Article  Google Scholar 

  33. 33.

    Yadav B, Wennerberg K, Aittokallio T, Tang J. Searching for drug synergy in complex dose-response landscapes using an interaction potency model. Comput Struct Biotechnol J. 2015;13:504–13.

    CAS  Article  Google Scholar 

  34. 34.

    Ianevski A, He L, Aittokallio T, Tang J. SynergyFinder: a web application for analyzing drug combination dose-response matrix data. Bioinformatics. 2017;33:2413–5.

    Article  Google Scholar 

  35. 35.

    Misale S, Bozic I, Tong J, Peraza-Penton A, Lallo A, Baldi F, et al. Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. Nat Commun. 2015;6:8305.

    CAS  Article  Google Scholar 

  36. 36.

    Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538:477–82.

    Article  Google Scholar 

  37. 37.

    Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, et al. Dissecting eIF4E action in tumorigenesis. Genes Dev. 2007;21:3232–7.

    CAS  Article  Google Scholar 

  38. 38.

    Ryan J, Letai A. BH3 profiling in whole cells by fluorimeter or FACS. Methods. 2013;61:156–64.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We thank, the patients and healthy donors for the samples, the technical staff for isolation of mononuclear cells from these samples, the FIMM High Throughput Biomedicine unit for drug screening of patient samples, and the FIMM Breeze team for data analysis. Aleksandr Ianevski for the analysis of drug synergy scores. Heikki Kuusanmäki for planning the experiments with patient samples clinically relapsed under azacitidine + venetoclax treatment. Professor Satu Mustjoki, Elina Parri, Heikki Kuusanmäki, and Amanda Ranta for help with the healthy peripheral blood mononuclear cell sample experiments. The project was supported by grants from Academy of Finland (KW; grant no. 277293), Novo Nordisk Foundation (KW Novo Nordisk Foundation Center for Stem Cell Biology, DanStem; grant no NNF17CC0027852), Cancer Foundation of Finland (KW), and Sigrid Juselius Foundation (KW). The Doctoral Programme in Biomedicine (DPBM) at the University of Helsinki (EK), University of Helsinki Early Career Grant (MK), and the Norwegian Cancer Society (BTG).

Author information

Affiliations

Authors

Contributions

MT, EK, and KW designed research; MT, EK, MV-K, and DB performed experiments and analyses. BTG, KP, MK, and CAH collected clinical samples and obtained ethical permits; KW supervised the study; MT, EK, and KW, wrote the manuscript; all the authors reviewed and approved the manuscript.

Corresponding author

Correspondence to Krister Wennerberg.

Ethics declarations

Conflict of interest

KW has received research funding from Novartis unrelated to this study. CAH has received research funding from Celgene, Novartis, Oncopeptides, and Orion Pharma unrelated to this study. BTG has received honoraria from Pfizer, Astellas, Daiichi Sankyo, Seattle Genetics, and BerGenBio and owns shares in KinN Therapeutics AS and ACTII AS. MK has received research funding from AbbVie unrelated to this study.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tambe, M., Karjalainen, E., Vähä-Koskela, M. et al. Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition. Leukemia (2020). https://doi.org/10.1038/s41375-020-0972-0

Download citation